New Antituberculosis Drugs: From Clinical Trial to Programmatic Use

Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Infectious Disease Reports Jg. 8; H. 2; S. 6569
Hauptverfasser:	Gualano, Gina, CAPONE, Susanna, MATTEELLI, Alberto, Palmieri, Fabrizio
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Italy MDPI AG 24.06.2016 PAGEPress Publications, Pavia, Italy
Schlagworte:	antituberculosis therapy Carbapenems Clinical outcomes Clinical trials Conversion Drug resistance Drugs Health services Linezolid Multidrug resistance Multidrug resistant organisms Multidrug-resistant Multidrug-resistant; antituberculosis therapy; new drugs; tuberculosis new drugs Nitroimidazole Other systems of medicine Review RZ201-999 Sputum Tuberculosis Multidrug-resistant antituberculosis therapy new drugs tuberculosis
ISSN:	2036-7449, 2036-7430, 2036-7449
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!